Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL ‐17: A new actor in IFN ‐driven systemic autoimmune diseases

1 Sept 2012

Abstract excerpt

Systemic autoimmune diseases such as systemic lupus erythematosus are type I IFN-driven diseases with exaggerated B-cell responses and autoantibody production. Th17 cells, a T-helper-cell subset with high inflammatory capacity, was initially discovered and characterized in the context of experimental autoimmune encephalomyelitis - an animal model of multiple sclerosis. There is now emerging evidence that Th17...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Psoriasis: Treatment and Pathogenesis
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22949326
DOI: 10.1002/eji.201242653

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL ‐17: A new actor in IFN ‐driven systemic autoimmune diseasesPMID 22949326Read ↗

Roles of T helper 17 cells and interleukin‐17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain‐Barré syndrome as well as their animal modelsSemantic proximity Read ↗

Insight Into Non-Pathogenic Th17 Cells in Autoimmune Diseases.Semantic proximity Read ↗

Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation.Semantic proximity Read ↗

The IL‐17 pathway as a major therapeutic target in autoimmune diseasesSemantic proximity Read ↗

Th17 Cell, the New Player of Neuroinflammatory Process in Multiple SclerosisSemantic proximity Read ↗

IL-17 in the Pathogenesis of Disease: Good Intentions Gone AwrySemantic proximity Read ↗

Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response.Semantic proximity Read ↗

The IL-17 family in diseases: from bench to bedsideSemantic proximity Read ↗

Development and function of interleukin 17-producing γδ T cells.Semantic proximity Read ↗

Pouring fuel on the fire: Th17 cells, the environment, and autoimmunitySemantic proximity Read ↗

Th1-related transcription factors and cytokines in systemic lupus erythematosusSemantic proximity Read ↗

Type III Interferons: Emerging Roles in AutoimmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.